Lymphoma: Dual-Targeting CAR T Shows Safety, Efficacy ...Middle East

Medscape - News
Lymphoma: Dual-Targeting CAR T Shows Safety, Efficacy
KITE-363, a dual-targeting CAR T-cell therapy, shows a strong safety profile and high responses in patients who have highly refractory large B-cell lymphoma, new research shows. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Lymphoma: Dual-Targeting CAR T Shows Safety, Efficacy )

Apple Storegoogle play

Also on site :



Latest News